News Archive: Cangene

Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene Names John A. Sedor as President and Chief Executive Officer

Aug 16, 2011

“John’s appointment is the culmination of a rigorous and thoughtful search process over the past six months,” says board chair, Craig Baxter. “We believe he is the ideal CEO for the Company. He is a visionary leader and strong manager who brings a successful track record of growing companies and efficiently managing them to create value for shareholders, customers, partners and employees.” [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

BARDA Exercises Options With Cangene Worth Us$61 Million Under Botulism Antitoxin Supply Contract

Jun 3, 2011

“This is an extremely positive step. Not only does this significantly increase the total revenue value of this contract, it also indicates that BARDA is adopting a strategy of extending these types of contracts to replenish supplies of biodefence products. As the supplier for three products in the U.S. Strategic National Stockpile, that’s an indication we are happy to see,” said Michael Graham, acting President and CEO of Cangene. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene Receives Approval to Early-Adopt International Financial Reporting Standards

Mar 17, 2011

Cangene announces that it has received approval from the Canadian securities regulatory authorities to prepare its financial statements in accordance with International Financial Reporting Standards (“IFRS”) for financial reporting periods beginning on or after January 1, 2010, one year ahead of the mandatory conversion date for Canadian public companies. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene Announces CEO Is Stepping Down

Jan 25, 2011

Effective immediately, Dr. Langstaff resigns from his position as President and CEO, and from the Board of Directors, but will continue as a special advisor to the Company. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene Announces Corporate Reorganization Within Its Plasma-Collection Centre Operations

Nov 5, 2010

“This change builds upon our strategy to strengthen our corporate brand in all our markets and for all our stakeholders. We had rebranded our plasma-centre operations as Cangene Plasma Resources; this reorganization formalizes the change and streamlines our corporate structure,” said Dr. John Langstaff, president and CEO of Cangene Corporation. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene Announces Results for Fiscal 2010; A Year of Change

Oct 27, 2010

“Our financial performance in 2010 reflects our investment in change that adds a new dimension to our business as we have brought our U.S. sales and marketing in-house for the first time in our history. We have also invested in pipeline development, particularly with respect to IGIV, a widely used anti-infective product that we believe will be a good complement to our hospital-based commercial product line-up. Our solid cash and debt-free position allowed us these opportunities to invest in our future growth,” said Dr. John Langstaff, president and CEO of Cangene. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene’s Hepatitis B product approved by European Commission

Mar 17, 2010

“This approval extends the reach of this product, which is our second largest selling commercial product in North America where it has two approved indications. While this market is relatively small compared with North America, this is nevertheless a positive development,” said Dr. John Langstaff, Cangene’s president and CEO. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene announces first quarter financial results for fiscal 2010

Dec 14, 2009

“The financial results for the quarter continue to reflect our delivery on the biodefence contracts in accordance with established schedules,” said Dr. John Langstaff, Cangene’s president and CEO. “We have also begun to focus more directly on the U.S. commercial markets, beginning with our acquisition of the U.S. commercialization rights for HepaGam B(R) from Apotex. [Click on Logo to learn more]

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Cangene (MOM Article)

Sep 16, 2009

A world leader in the development , manufacture, and commercialization of specialty hyperimmune plasma and biotechnology products.

read more
Cangene Names John A. Sedor as President and Chief Executive Officer

Manitoba Promoted as Major Hub of Knowledge and Innovation

May 19, 2009

Premier Gary Doer is promoting Manitoba as a major hub of knowledge, research and innovation at the 2009 BIO International Conference, where he is leading a delegation that includes more than 30 leaders from the province’s life-sciences industry, research and post-secondary education sectors.

read more